Antiepileptic Flashcards
Brivaracetam
Synaptic vesicle protein 2A
Angioedema, Neutropenia
Lower in hepatic
C-V controlled substance
Cannabidiol
MOA: Unknown
Anemia, Hepatotoxicity, Infections
Used in Lannox-Gastaut or Dravet
Highly protein bound
Mod 2C19 inhibitor
Lower in hepatic
Carbamazepine (MOA & ADRs)
Na channel
Agranulocytosis
Aplastic anemia, Leukopenia
DRESS, SJS/TEN
HYPOnatremia
Hyperhomocysteinemia
Osteoporosis
Weight GAIN
Squamous cell carcinoma
Carbamazepine (Clinical Pearls)
HLA-B1502 & HLA-A3101 testing prior to initiation (esp in Asians)
Inducer of 2B6 & 3A4
Auto-induces it’s own metabolism (increase dose over 3-4 weeks)
Therapeutic range: 4-12 mcg/mL
Highly protein bound
CI: bone marrow suppression
Cenobamate
Na channel and GABA
C-V controlled substance
Shorten QT interval, HYPERkalemia, DRESS, Diplopia
Lower in hepatic/renal, Avoid in hepatic
CI: QT shortening
Inhibits 2C19
Induces 3A4
Clobazam
GABA
SJS/TEN
Titrate slowly with hepatic
Tolerance
Highly protein bound
C-IV controlled substance
Eslicarbazepine
Na channel
Agranulocytosis
DRESS, SJS/TEN
Hepatotoxicity
HYPOnatremia
Hypothyroidism
Lower in renal
Induces 3A4
Ethosuximide
Ca channel
Aplastic anemia, Leukopenia
DRESS, SJS/TEN
Systemic lupus erythematous
Hepatotoxicity, Nephrotoxicity
May also be effective in myoclonic seizures
Therapeutic range: 40-100 mcg/mL
Felbamate
Glutamate
Aplastic anemia, Leukopenia, Thrombocytopenia
SJS/TEN
Hepatotoxicity
Weight LOSS
Lower in renal
CI: pts with hepatic dysfunction or blood dyscrasia(s)
Gabapentin
Ca channel
Angioedema
DRESS
Pancreatitis
Weight GAIN
Lower in renal
Lacosamide
Na channel and CRMP-2
DRESS
Arrhythmias, AV block, PR interval prolongation
Lower in renal & hepatic, Avoid in hepatic
C-V controlled substance
Lamotrigine (MOA & ADRs)
Na channel and glutamate
Aseptic meningitis
Blood dyscrasias
DRESS, SJS/TEN
Hemophagocytic lymphohistiocytosis
Squamous cell carcinoma
Lamotrigine (Clinical Pearls)
Initial dosing:
a) LOWER if on valproic acid
b) HIGHER if on carbamazepine, phenytoin, phenobarbital or primidone
Lower in hepatic
Oral contraceptives may reduce concentrations
Levetiracetam
Synaptic vesicle protein 2A
Blood dyscrasias
SJS/TEN
Lower in renal
Oxcarbazepine (MOA & ADRs)
Na & Ca channels
Blood dyscrasias
DRESS, SJS/TEN
Hepatotoxicity
HYPOnatremia
Hypothyroidism
Osteoporosis
Oxcarbazepine (Clinical Pearls)
Lower in renal
HLA-B1502 & HLA-A3101 testing
Active form: 10-monohydroxy metabolite
Perampanel
Glutamate
DRESS
Behavioral problems
Suicidal/homicidal ideation
Lower in hepatic, Avoid in hepatic
Highly protein bound
C-III controlled substance
Phenobarbital (MOA & ADRs)
GABA and Na channel
Aplastic anemia, Leukopenia
SJS/TEN
Hyperhomocysteinemia
Osteoporosis
Phenobarbital (Clinical Pearls)
Primidone is metabolized to phenobarbital
IV preparation contains propylene glycol
Lower in renal & hepatic
CI: severe hepatic, porphyria, and airway obstruction
Induces 3A4 (strong)
Therapeutic range: 10-40 mcg/mL
C-IV controlled substance
Phenytoin (MOA & ADRs)
Na channel
Blood dyscrasias
DRESS, SJS/TEN
Hepatotoxicity
Hyperhomocysteinemia
Lymphadenopathy
Osteoporosis
Gingival hyperplasia
Phenytoin (Clinical Pearls)
IV preparation contains propylene glycol
Phenytoin is a vesicant (SC/IM not recommended)
Lower in hepatic
HLA-B*1502 & 2C9 - associated with SJS/TEN
Inducer of 3A4 (strong)
Zero-order PK
Therapeutic range: 10-20 mcg/mL (total) or 1-2 mcg/mL (free)
Highly protein bound
Pregabalin
Ca channel
Angioedema
Peripheral edema
Rhabdomyolysis
PR interval prolongation
Thrombocytopenia
Visual field defects
Lower in renal
C-V controlled substance
Rufinamide
Na channel
DRESS, SJS/TEN
Leukopenia
QT shortening
Avoid in hepatic
CI: Shorten QT interval
Tiagabine
GABA
SJS/TEN, suicidal ideation, infections
Lower in hepatic
Highly protein bound
Topiramate
Na channel, glutamate, & GABA
Acute glaucoma
Decrease serum bicarbonate levels
Metabolic acidosis
Nephrolithiasis
Oligohidrosis
SJS/TEN
TERATOGENICITY
Lower in hepatic & renal
Valproic Acid (MOA & ADRs)
Na channel & GABA
DRESS
Hepatotoxicity
Hypothermia
Osteoporosis
Pancreatitis
TERATOGENICITY
Thrombocytopenia
Weight GAIN
Valproic Acid (Clinical Pearls)
Highly protein bound
Avoid in hepatic
CI: hepatic dysfunction, urea cycle disorders, mitochondrial disease
Therapeutic range: 50-150 mcg/mL
Vigabatrin
GABA
Weight GAIN
REMS: Visual field deficits or permanent loss
Lower in renal
Zonisamide
Na & Ca channels
DRESS, SJS/TEN
Metabolic acidosis
Nephrolithiasis
Nephrotoxicity
Oligohidrosis
Lower in hepatic, Avoid in renal
Contains sulfa moiety